Publication:

Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy

Loading...
Thumbnail Image

Open/View Files

Date

2017

Journal Title

Journal ISSN

Volume Title

Publisher

Public Library of Science
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Makker, Preet G. S., Samuel S. Duffy, Justin G. Lees, Chamini J. Perera, Ryan S. Tonkin, Oleg Butovsky, Susanna B. Park, David Goldstein, and Gila Moalem-Taylor. 2017. “Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy.” PLoS ONE 12 (1): e0170814. doi:10.1371/journal.pone.0170814. http://dx.doi.org/10.1371/journal.pone.0170814.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) and associated neuropathic pain is a debilitating adverse effect of cancer treatment. Current understanding of the mechanisms underpinning CIPN is limited and there are no effective treatment strategies. In this study, we treated male C57BL/6J mice with 4 cycles of either Paclitaxel (PTX) or Oxaliplatin (OXA) over a week and tested pain hypersensitivity and changes in peripheral immune responses and neuroinflammation on days 7 and 13 post 1st injection. We found that both PTX and OXA caused significant mechanical allodynia. In the periphery, PTX and OXA significantly increased circulating CD4+ and CD8+ T-cell populations. OXA caused a significant increase in the percentage of interleukin-4+ lymphocytes in the spleen and significant down-regulation of regulatory T (T-reg) cells in the inguinal lymph nodes. However, conditional depletion of T-reg cells in OXA-treated transgenic DEREG mice had no additional effect on pain sensitivity. Furthermore, there was no leukocyte infiltration into the nervous system of OXA- or PTX-treated mice. In the peripheral nervous system, PTX induced expression of the neuronal injury marker activating transcription factor-3 in IB4+ and NF200+ sensory neurons as well as an increase in the chemokines CCL2 and CCL3 in the lumbar dorsal root ganglion. In the central nervous system, PTX induced significant astrocyte activation in the spinal cord dorsal horn, and both PTX and OXA caused reduction of P2ry12+ homeostatic microglia, with no measurable changes in IBA-1+ microglia/macrophages in the dorsal and ventral horns. We also found that PTX induced up-regulation of several inflammatory cytokines and chemokines (TNF-α, IFN-γ, CCL11, CCL4, CCL3, IL-12p70 and GM-CSF) in the spinal cord. Overall, these findings suggest that PTX and OXA cause distinct pathological changes in the periphery and nervous system, which may contribute to chemotherapy-induced neuropathic pain.

Description

Research Data

Keywords

Biology and Life Sciences, Anatomy, Nervous System, Neuroanatomy, Spinal Cord, Medicine and Health Sciences, Neuroscience, Physiology, Immune Physiology, Cytokines, Immunology, Immune System, Innate Immune System, Developmental Biology, Molecular Development, Cell Biology, Cellular Types, Animal Cells, Blood Cells, White Blood Cells, T Cells, Immune Cells, Lymphocytes, Pharmaceutics, Drug Therapy, Chemotherapy, Diagnostic Medicine, Signs and Symptoms, Pain, Neuropathic Pain, Pathology and Laboratory Medicine, Cell Motility, Chemotaxis, Chemokines, Clinical Medicine, Clinical Immunology, Hypersensitivity

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories